 |
PDBsum entry 3g33
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Cell cycle
|
 |
|
Title:
|
 |
Crystal structure of cdk4/cyclin d3
|
|
Structure:
|
 |
Cell division protein kinase 4. Chain: a, c. Synonym: cyclin-dependent kinase 4, psk-j3. Engineered: yes. Ccnd3 protein. Chain: b, d. Synonym: cyclin d3, isoform cra_b. Engineered: yes
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Gene: cdk4. Expressed in: spodoptera frugiperda. Expression_system_taxid: 7108. Gene: ccnd3, hcg_16683. Expression_system_taxid: 7108
|
|
Resolution:
|
 |
|
3.00Å
|
R-factor:
|
0.283
|
R-free:
|
0.314
|
|
|
Authors:
|
 |
T.Takaki,A.Echalier,N.R.Brown,T.Hunt,J.A.Endicott,M.E.M.Noble
|
Key ref:
|
 |
T.Takaki
et al.
(2009).
The structure of CDK4/cyclin D3 has implications for models of CDK activation.
Proc Natl Acad Sci U S A,
106,
4171-4176.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
01-Feb-09
|
Release date:
|
10-Mar-09
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class 1:
|
 |
Chains A, C:
E.C.2.7.11.22
- cyclin-dependent kinase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
|
1.
|
L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H+
|
|
2.
|
L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H+
|
|
 |
 |
 |
 |
 |
L-seryl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-seryl-[protein]
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
L-threonyl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-threonyl-[protein]
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Enzyme class 2:
|
 |
Chains B, D:
E.C.?
|
|
 |
 |
 |
 |
 |
 |
 |
|
Note, where more than one E.C. class is given (as above), each may
correspond to a different protein domain or, in the case of polyprotein
precursors, to a different mature protein.
|
|
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Proc Natl Acad Sci U S A
106:4171-4176
(2009)
|
|
PubMed id:
|
|
|
|
|
| |
|
The structure of CDK4/cyclin D3 has implications for models of CDK activation.
|
|
T.Takaki,
A.Echalier,
N.R.Brown,
T.Hunt,
J.A.Endicott,
M.E.Noble.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Cyclin-dependent kinase 4 (CDK4)/cyclin D complexes are expressed early in the
G(1) phase of the cell cycle and stimulate the expression of genes required for
G(1) progression by phosphorylation of the product of the retinoblastoma gene,
pRb. To elaborate the molecular pathway of CDK4 activation and substrate
selection we have determined the structure of nonphosphorylated CDK4/cyclin D3.
This structure of an authentic CDK/cyclin complex shows that cyclin binding may
not be sufficient to drive the CDK active site toward an active conformation.
Phosphorylated CDK4/cyclin D3 is active as a pRb kinase and is susceptible to
inhibition by p27(Kip1). Unlike CDK2/cyclin A, CDK4/cyclin D3 can be inactivated
by treatment with lambda-phosphatase, implying that phosphorylated T172 is
accessible to a generic phosphatase while bound to a cyclin. Taken together,
these results suggest that the structural mechanism of CDK4/cyclin D3 activation
differs markedly from that of previously studied CDK/cyclin complexes.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 1.
Structure and substrate selection in CDK4/cyclin D3. (A) The
fold of CDK4/cyclin D3 (left side) is compared with that of
CDK2/cyclin A in complex with a substrate peptide (PDB ID code
1QMZ; right side). Important structural and regulatory elements
referred to in the text are indicated on each structure and
correspond to the CDK N-lobe (light gray), the C-helix (cyan),
the CDK C-lobe (yellow), the activation segment (red), and the
cyclin subunit (green). (B) The activity of CDK4/cyclin D3
toward pRb family members highly depends on substrate
recruitment. See Results for details.
|
 |
Figure 2.
Comparison of the structures of monomeric CDK2, CDK4/cyclin
D3, and T160pCDK2/cyclin A. The 3 structures are viewed looking
down onto the CDK C-terminal domain from the N-terminal domain
and are colored according to the scheme used in Fig. 1. (A)
Monomeric CDK2. (B) CDK4/cyclin D3. (C) T160pCDK2/cyclin A. The
figure highlights the displacement of the CDK4/cyclin D3
activation segment away from the active conformation present in
T160pCDK2/cyclin A and its similarity to the structure of the
activation segment in monomeric CDK2 (monomeric T160pCDK2 PDB ID
code 1HCK).
|
 |
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
E.A.Musgrove,
C.E.Caldon,
J.Barraclough,
A.Stone,
and
R.L.Sutherland
(2011).
Cyclin D as a therapeutic target in cancer.
|
| |
Nat Rev Cancer,
11,
558-572.
|
 |
|
|
|
|
 |
N.Jura,
X.Zhang,
N.F.Endres,
M.A.Seeliger,
T.Schindler,
and
J.Kuriyan
(2011).
Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms.
|
| |
Mol Cell,
42,
9.
|
 |
|
|
|
|
 |
Y.Wang,
J.C.Fisher,
R.Mathew,
L.Ou,
S.Otieno,
J.Sublet,
L.Xiao,
J.Chen,
M.F.Roussel,
and
R.W.Kriwacki
(2011).
Intrinsic disorder mediates the diverse regulatory functions of the Cdk inhibitor p21.
|
| |
Nat Chem Biol,
7,
214-221.
|
 |
|
|
|
|
 |
K.A.Merrick,
and
R.P.Fisher
(2010).
Putting one step before the other: distinct activation pathways for Cdk1 and Cdk2 bring order to the mammalian cell cycle.
|
| |
Cell Cycle,
9,
706-714.
|
 |
|
|
|
|
 |
F.Cesari
(2009).
Change of guard at the checkpoint.
|
| |
Nat Rev Mol Cell Biol,
10,
305.
|
 |
|
|
|
|
 |
L.Bockstaele,
X.Bisteau,
S.Paternot,
and
P.P.Roger
(2009).
Differential regulation of cyclin-dependent kinase 4 (CDK4) and CDK6, evidence that CDK4 might not be activated by CDK7, and design of a CDK6 activating mutation.
|
| |
Mol Cell Biol,
29,
4188-4200.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
|
');
}
}
 |
|